Teva settles litigation but keeps manufacturing on hold
Teva and Amgen’s patent infringement litigation will come to a close after the former agreed to stop selling its generic cinacalcet HCI product until 2021. Teva will also pay Amgen an undisclosed amount as part of the settlement process whilst other terms of the settlement remain confidential.
The two companies’ litigation regarded the selling of Teva’s generic of Amgen’s product Sensipar, a calcium-sensing receptor agonist. Sensipar, and its generics are used in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. The product can also be used for patients with parathyroid carcinoma and severe hypercalcemia.
Per the settlement, Teva is currently unable to manufacture and sell two of its generic products until 2021 when manufacturing will begin again.
After the news of the settlement, Teva’ share price was up 2.79% on the New York Stock Exchange as the market closed.
This is not the first settlement for Teva in recent months. In December 2018, Teva also settled another patent infringement litigation regarding its selling of a generic version of Neos’ ADHD drug Cotempla (methylphenidate).
Teva’s settlement with Neos’ resolved that Teva is unable to manufacture and sell the Cotempla generic until July 1, 2026.
While the company has put a hold on manufacturing and selling of three of its generic products, Teva will continue on with its release of its EpiPen generic. Teva released the market price of its EpiPen generic, the first EpiPen generic aside from the brand name manufacturer, Mylan’s, generic.
